Xenon's Azetukalner Cuts Seizure Frequency by 53% in Phase 3 Trial, Poised for First-in-Class FDA Submission

Overview

Xenon Pharmaceuticals presented full Phase 3 results for azetukalner at the American Academy of Neurology Annual Meeting in Chicago on April 19, 2026, showing the drug cut monthly focal onset seizure frequency by 53 percent at its higher dose versus 10 percent on placebo. The data support an FDA new drug application the company plans to file in the third quarter of 2026, which would make azetukalner the first potassium channel opener approved for epilepsy in nearly a decade and the first drug in its class to survive regulatory scrutiny.

What the Trial Found

The X-TOLE2 study enrolled 380 adults with highly treatment-resistant focal epilepsy — a population averaging five prior anti-seizure medications and a baseline of nearly 13 seizures per month. Over a 12-week double-blind period, the 25 mg dose of azetukalner produced a median reduction in monthly seizure frequency of 53.2 percent, and the 15 mg dose produced a 34.5 percent reduction, compared with 10.4 percent in the placebo group, according to Xenon’s press release.

The placebo-adjusted effect at the higher dose reached 42.7 percentage points, which BioPharma Dive reported Stifel analyst Paul Matteis called “a home run” and “way above investor expectations.” Xenon shares rose approximately 50 percent on the day the top-line data were released in March.

Half the patients in the higher-dose arm achieved at least a 50 percent reduction in monthly seizures — the conventional responder threshold in epilepsy trials — compared with 21 percent on placebo. More than 6 percent of patients given the 25 mg dose had complete seizure control during the study, versus under 1 percent on placebo, as stated in Xenon’s press release.

Along with the Phase 3 results, Xenon presented 48-month long-term data from the X-TOLE open-label extension. Among 131 participants who remained on treatment for at least four years, median seizure frequency had fallen 90.9 percent from baseline by month 48. Some 38 percent of long-term participants achieved clinically defined seizure freedom — at least 12 consecutive seizure-free months — and a quarter maintained that status for at least two years, per the press release.

How the Drug Works

Azetukalner opens KV7 potassium channels in the central nervous system. When these channels are activated, potassium flows out of neurons, hyperpolarizing the cell membrane and making it harder for neurons to fire. In epilepsy, runaway neuronal firing generates seizures; azetukalner dampens that excitability at the channel level. Xenon’s chief medical officer Chris Kenney noted the results were “particularly striking” given that the patient population included a substantial share who had already tried and discontinued cenobamate, currently the most potent approved add-on epilepsy drug, according to Xenon’s press release.

Nearly 40 percent of X-TOLE2 participants had taken cenobamate and 19 percent had stopped it before enrolling, meaning many had already exhausted the most recent generation of add-on options.

Approximately 20 anti-seizure medications are currently on the market, but the vast majority work through two primary mechanisms: blocking voltage-gated sodium channels or binding the synaptic vesicle protein SV2A. The KV7 pathway operates differently, which Xenon has positioned as potentially additive rather than redundant for patients already on multiple agents.

Regulatory and Safety Context

The drug class has a complicated history. Ezogabine, an earlier KV7 opener marketed as Potiga, was withdrawn in 2017 after causing blue-grey discoloration of skin, mucous membranes, and retinal abnormalities. In X-TOLE2, no notable skin discoloration, retinal abnormalities, or cardiovascular events were observed, as reported in Xenon’s press release. The most common adverse events were dizziness (20.5 percent versus 3.2 percent on placebo), headache, somnolence, and fatigue. Serious adverse event rates were low across all arms.

The drug also requires no dose titration and no adjustments when co-administered with other anti-seizure medications, simplifying prescribing for a population on complex polypharmacy regimens. Survey data presented at the meeting showed 90 percent of patients agreed that a titration-free option would improve their confidence in a new treatment, and 84 percent reported better expected adherence, as noted in Xenon’s press release.

Unmet Need in Focal Epilepsy

Focal onset seizures, which originate in a specific brain region, represent the most common epilepsy type in adults. Despite roughly 20 available medications, drug resistance remains prevalent: a systematic review and meta-analysis in Neurology found that drug-resistant epilepsy affected approximately 36 percent of patients in clinic-based cohorts, with focal epilepsy carrying higher resistance rates than generalized epilepsy forms, according to the study on PubMed. The X-TOLE2 population, averaging five prior medications and nearly 13 seizures per month, reflects the depth of treatment failure that the current pharmacopeia cannot address.

What Comes Next

Xenon plans to submit a new drug application to the FDA in the third quarter of 2026, as stated in its official press release. The NDA will be supported by the Phase 2b X-TOLE study, the Phase 3 X-TOLE2 trial, and open-label extension data totaling more than 775 patient-years of exposure.

If approved, azetukalner would be the first KV7 potassium channel opener available for epilepsy since ezogabine’s withdrawal, and the first to enter the market with safety data specifically addressing the skin and retinal signals that ended its predecessor’s commercial life. Whether the prescribing community treats the outcome as vindication of the KV7 mechanism — or remains cautious given the class’s track record — will depend partly on how post-approval surveillance data accumulate and whether BioPharma Dive’s assessment of the “home run” trial result translates into clinical uptake.